Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
复制标题
DOI：
10.1016/j.vaccine.2022.09.021
复制
发表时间：
2022-10-06
期刊：
影响因子：
5.5
通讯作者：
Berry, Andrea A.
中科院分区：
文献类型：
--
作者：
Friedman-Klabanoff, Deanna J.;Tjaden, Ashley H.;Santacatterina, Michele;Munawar, Iqra;Sanders, John W.;Herrington, David M.;Wierzba, Thomas F.;Berry, Andrea A.
监管良好的临床试验表明，FDA批准的COVID-19疫苗具有免疫原性和高度有效性。我们在一项针对居住在北卡罗来纳州的近8000名成年人的队列研究中评估了报告≥ 1剂mRNA COVID-19疫苗的成年人的血清转换率，以使用一种新方法验证免疫原性：在家中，参与者进行即时检测。总体而言，91.4%的人在首次接种疫苗后75天内（中位数：31天）记录到血清转化。年龄较大的男性参与者不太可能发生血清转化（41-65岁成人：校正风险比[aHR] 0.69 [95%置信区间（CI）：0.64，0.73]，66-95岁成人：aHR 0.55 [95% CI：0.50，0.60]，与18-40岁成人相比;男性：aHR 0.92 [95% CI：0.87，0.98]，与女性相比）。有既往感染证据的参与者比没有感染证据的参与者更可能发生血清转化（aHR 1.50 [95% CI：1.19，1.88]），而接受BNT 162 b2的参与者与接受mRNA-1273的参与者相比发生血清转化的可能性更低（aHR 0.84 [95% CI：0.79，0.90]）。首次接种后报告至少一种新症状不影响血清转化时间，但第二次接种后报告至少一种新症状的参与者更有可能发生血清转化（aHR 1.11 [95% CI：1.05，1.17]）。这些数据表明，COVID-19疫苗具有较高的社区免疫原性，尽管在老年人中存在显著差异，以及使用在家参与者管理的床旁检测进行社区队列监测的可行性。试验注册：ClinicalTrials.gov NCT 04342884。
Well-regulated clinical trials have shown FDA-approved COVID-19 vaccines to be immunogenic and highly efficacious. We evaluated seroconversion rates in adults reporting ≥ 1 dose of an mRNA COVID-19 vaccine in a cohort study of nearly 8000 adults residing in North Carolina to validate immunogenicity using a novel approach: at-home, participant administered point-of-care testing. Overall, 91.4% had documented seroconversion within 75 days of first vaccination (median: 31 days). Participants who were older and male participants were less likely to seroconvert (adults aged 41–65: adjusted hazard ratio [aHR] 0.69 [95% confidence interval (CI): 0.64, 0.73], adults aged 66–95: aHR 0.55 [95% CI: 0.50, 0.60], compared to those 18–40; males: aHR 0.92 [95% CI: 0.87, 0.98], compared to females). Participants with evidence of prior infection were more likely to seroconvert than those without (aHR 1.50 [95% CI: 1.19, 1.88]) and those receiving BNT162b2 were less likely to seroconvert compared to those receiving mRNA-1273 (aHR 0.84 [95% CI: 0.79, 0.90]). Reporting at least one new symptom after first vaccination did not affect time to seroconversion, but participants reporting at least one new symptom after second vaccination were more likely to seroconvert (aHR 1.11 [95% CI: 1.05, 1.17]). This data demonstrates the high community-level immunogenicity of COVID-19 vaccines, albeit with notable differences in older adults, and feasibility of using at-home, participant administered point-of-care testing for community cohort monitoring. Trial registration: ClinicalTrials.gov NCT04342884.
登录
查看更多内容
影响因子：
5.5
作者：
Shachor-Meyouhas Y;Hussein K;Szwarcwort-Cohen M;Weissman A;Mekel M;Dabaja-Younis H;Hyams G;Horowitz NA;Kaplan M;Halberthal M
通讯作者：
Halberthal M
影响因子：
5.5
作者：
Tani N;Chong Y;Kurata Y;Gondo K;Oishi R;Goto T;Minami J;Onozawa K;Nagano S;Shimono N;Ikematsu H;Kuwano H
通讯作者：
Kuwano H
DOI：
10.2807/1560-7917.es.2021.26.6.2100096
发表时间：
2021-03
期刊：
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
影响因子：
--
作者：
Abu Jabal K;Ben-Amram H;Beiruti K;Batheesh Y;Sussan C;Zarka S;Edelstein M
通讯作者：
Edelstein M
DOI：
10.1093/infdis/jiab314
发表时间：
2021-09-01
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Demonbreun AR;Sancilio A;Velez ME;Ryan DT;Pesce L;Saber R;Vaught LA;Reiser NL;Hsieh RR;D'Aquila RT;Mustanski B;McDade TW;McNally EM
通讯作者：
McNally EM
DOI：
10.1056/nejmoa2027906
发表时间：
2020-12-17
期刊：
The New England journal of medicine
影响因子：
--
作者：
Walsh EE;Frenck RW Jr;Falsey AR;Kitchin N;Absalon J;Gurtman A;Lockhart S;Neuzil K;Mulligan MJ;Bailey R;Swanson KA;Li P;Koury K;Kalina W;Cooper D;Fontes-Garfias C;Shi PY;Türeci Ö;Tompkins KR;Lyke KE;Raabe V;Dormitzer PR;Jansen KU;Şahin U;Gruber WC
通讯作者：
Gruber WC